NCT00331643View on ClinicalTrials.gov

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

June 30, 2009

Conditions
Adult RhabdomyosarcomaAdult Synovial SarcomaAlveolar Childhood RhabdomyosarcomaChildhood Synovial SarcomaEmbryonal Childhood RhabdomyosarcomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions
DRUG

ixabepilone

Given IV

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00331643 - Ixabepilone in Treating Young Patients With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter